Recombinant factor vila (novoseven®) in the treatment of internal bleeding in patients with factor VIM and IX inhibitors

Pathophysiology of Haemostasis and Thrombosis

Volumn 26, Issue , 1996, Pages 124-130

  Lusher, Jeanne M ^a   Compassionate, Novo Seven ^a   Investigators, Use ^a  

^a CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

Author keywords

Iliopsoas hemorrhage; Intra abdominal bleeding; Retroperitoneal hemorrhage

Indexed keywords

BLOOD CLOTTING FACTOR INHIBITOR; RECOMBINANT BLOOD CLOTTING FACTOR 7A; UNCLASSIFIED DRUG;

BLEEDING; CLINICAL ARTICLE; CONFERENCE PAPER; HEMOPHILIA; HUMAN; PERITONEUM; PRIORITY JOURNAL;

ANTIBODY FORMATION; FACTOR IX; FACTOR VIIA; FACTOR VIII; HEMORRHAGE; HUMANS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0029912587     PISSN: 14248832     EISSN: 14248840     Source Type: Journal    
DOI: 10.1159/000217253     Document Type: Article

References (17)

1. Lusher JM. Arkin S, Abildgaard CF, Schwartz RS, Kogenate Previously Untreated Patient Study Group: Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. N Engl J Med 1993;328:453-459.
2. Bray G. Gompcrts ED, Courter S, Gruppo R, Gordon EM, Manco-Johnson M, Shapiro A, Scheibcl E. Lee M, Recombinate Study Group: A multicenter study of recombinant factor VIII (Recombinate): Safety, efficacy and inhibitor risk in previously untreated patients with hemophilia A. Blood 1994:83:2428-2435.
3. Ehrenforth S, Kreuz W, Scharrer I. Linda R, Funk M. Gungor T, Krack-hardt B. Kornhuber B: Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992;339:594-598.
4. Addiego J, Kasper C, Abildgaard CF, Hilgartner M, Lusher J, Glader B, Aledort L: Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII. Lancet 1993;342:462-464.
5. Hoyer LW: The incidence of factor VIII inhibitors in patients with severe hemophilia A; in Aledort L, Hoyer L, Rcisncr H, Lusher JM, White GC (eds): Inhibitors to Coagulation Factors. New York, Plenum Press, in press.
6. Chavin S, Siegel DM. Rocco TA Jr. Olson J: Acute myocardial infarction during treatment with an activated prothrombin complex concentrate in a patient with FV11I deficiency and FVIII inhibitor. Am J Med 1989;85:245-249.
7. Lusher JM: Thrombogenicity associated with factor IX complex concentrates. Semin Hematol 1991:28: 3-5.
8. Lusher JM, Kessler CM, Laurian Y, Pierce G: Viral contamination of blood products. Lancet 1994:344: 405-406.
9. Mannucci PM: Viral safety of plasma-derived and recombinant products used in the management of haemophilia A and B. Haemophilia 1995; 1(supp1 1): 14-20.
10. Kernoff PBA: Porcine factor VIII: Preparation and use in treatment of inhibitor patients. Prog Clin Biol Res 1984;150:207-224.
11. Gringeri A, Santagostino E, Tradati F, Giangrandc PLF, Mannucci PM: Adverse effects of treatment with porcine factor VIII. Thromb Hae-most 1991;65:245-247.
12. Hedner U, Glazer S, Pingel K: Successful use of recombinant factor Vila in a patient with severe haemophilia A during synovectomy. Lancet 1988;vol ii: 1193.
13. Lindley CM, Sawyer WT, Macik G. Lusher J. Harrison JF, Baird-Cox K, Birch K, Glazer S, Roberts HR: Pharmacokinetics and pharmacodynamics of recombinant factor Vila. Clin Pharmacol Ther 1994:55:638-648.
14. Lusher JM, Roberts HR. Smith H, Joist H, Davignon G: A randomized double-blind comparison of two dosage levels of recombinant factor Vila in the treatment of joint, muscle and mucocutaneous hemorrhages in persons with hemophilia A and B, with and without inhibitors. Blood, in press.
15. Hedner U, Feldstedt M, Glazer S: Recombinant F Vila in hemophilia treatment; in Lusher JM, Kessler CM (eds): Hemophilia and von Wil-lcbrand’s Disease in the 1990s. Amsterdam, Excerpta Medica Int Congr Ser, 1991. No. 943. pp 283-292.
16. Hedner U, Glazer S: Management of hemophilia patients with inhibitors. Hematol Oncol Clin North Am 1992;6:1035-1046.
17. Hedner U, Glazer S, Falch J: Recombinant activated factor VII in the treatment of bleeding episodes in patients with inherited and acquired bleeding disorders. Transfus Med Rev 1993;7:78.